standard
semaglutide metformin
Overview
Evidence is being populated by Grok web search.
Sources
- The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease“The combination of semaglutide and metformin significantly improves liver inflammation, fibrosis, and beta-cell function in patients with T2DM and NAFLD”
- Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial“Compared to MET monotherapy, combination therapy with semaglutide and MET significantly reduced body weight, improved insulin resistance, decreased ...”
- Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study“The results indicate that combining 1 mM metformin with either 10 nM semaglutide or 10 nM tirzepatide significantly enhances the effects of 10 nM semaglutide”
- Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)“Generic semaglutide demonstrated non-inferior efficacy and comparable safety to innovator Semaglutide in Indian adults with T2DM inadequately controlled on metformin”
- Effect of semaglutide with metformin for weight loss and ...“In this study , we demonstrated a significant efficacy of combined treatment with subcutaneous semaglutide and metformin in effective weight reduction and ...”
- Semaglutide Plus Low-Dose Metformin Combination ...“At 5 months after initiation of the combination therapy, blood tests showed metabolic improvements, including improvement of prediabetes (0.3- ...”
- Semaglutide Plus Metformin Versus ...“38.7% (12/31) of patients in the monotherapy group achieved the primary outcome of weight loss ≥ 5% from baseline vs. 61.29% (19/31) in the ...”
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial“This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individuals with type 2 diabetes inadequately controlled with metformin.”
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study“Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more”
- Semaglutide Injection in Indian Patients With Type 2 Diabetes Inadequately Controlled on Metformin“... metformin therapy and diet & exercise control were randomised (1:1) to receive subcutaneous injections of Test semaglutide or Reference semaglutide once ...”
- Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a systematic review and network meta-analysis“2.4 mg of semaglutide SC and 15 mg of tirzepatide were the best option among the included interventions considering favorable glucose and BMI control.”
- GLP1R and OCT1 variants modulate semaglutide and metformin weight loss response: a pharmacogenetic study“Semaglutide outperformed metformin for short-term weight loss . An HDL signal for OCT1 rs34130495 at an exploratory 10% FDR warrants replication.”
- Neuroprotective effects of semaglutide and metformin in a Parkinson's disease model“Pre-existing diabetes raises the likelihood of Parkinson's disease (PD), according to epidemiological and animal research. Our study aimed to investigating ...”
- Efficacy and safety of semaglutide injection in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials“Semaglutide combined with metformin significantly enhances the efficacy of treatment in T2DM patients, with marked improvements in C-Peptide levels, glycemic ...”
- Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data“Mean age was 65 years, diabetes duration 10 years, baseline HbA1c 7.6%, BMI 29 kg/m2, and 94% were on metformin.”